Liver Diseases  >>  tilsotolimod (IMO-2125)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tilsotolimod (IMO-2125) / Idera
NCT00728936: Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

Completed
1
58
US
IMO-2125, Saline placebo
Idera Pharmaceuticals, Inc.
Hepatitis C
12/09
05/10
NCT00990938: Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Completed
1
63
Europe
IMO-2125, Saline
Idera Pharmaceuticals, Inc.
Hepatitis C, Treatment Naïve, Genotype 1 Patients
05/10
01/11

Download Options